



MARK P. FLETCHER, M.D.

Job Title: Executive Director, Head Clinical Immuno-vaccinology Consulting Group; Chair BioTx Safety Council		Date: 20 February 2007
Full Name:	FLETCHER, MARK P.	
Date When Position First Held: Feb 2007		
Professional Address: Pfizer Inc 50 Pequot Avenue New London, CT 06320		
Academic Qualifications		
Degree/Certification, Field	Date	Institution, Country
Board Certification: Allergy/ Immunology	1981	American Board of Allergy and Clinical Immunology
Board Certification: Internal Medicine	1979	American Board of Internal Medicine
M.D.	June 1976	University of California, Davis, School of Medicine
B. S., Chemistry and Biochemistry, Summa cum laude	June 1972	University of California, Riverside.
Other Relevant Positions Held Within The Previous 10 Years:		
Dates (Yrs.)	Title	Department, Institution or Company, Country
Aug 05-Feb 07	Exec. Dir. Therapeutic Area Clinical Lead for Inflammation ,	
Mar 04-July 05	Exec. Dir. PGRD, Pfizer Inc; Clinical Exploratory Head, Immunology, RAIID GIGU	
2003- Feb 04	Exec. Dir. PGRD, Pfizer Inc; Full Dev Team Leader (FDTL), CDP-870 (TNF alpha blocker)	
2002-2003	Sr. Dir., Global R&D, Pfizer Inc; FDTL, CDP-870 (TNF alpha blocker)	
2000-2003	Dir./Sr. Dir. Clinical Research, Global R&D, Pfizer Inc; Global Clin. Leader, COX-2 Alliance	
1998-2000	Sr. Assoc Dir Clinical Research, Central Research, Pfizer Inc	
1997-1998	Deputy Dir., Clin. Res., Biological Products, Bayer Corp, Pharma Division, West Haven, CT.	
1994-1998	Assoc Dir. Clinical Res., Bayer Corp, Pharma Division, Biological Products Berkeley, CA Clinical Professor of Medicine, Division of Rheumatology Allergy and Clinical Immunology School of Medicine, University of California, Davis	
1982-1994.....	Faculty Division of Rheumatology, Allergy and Clinical Immunology, University of California, Davis School of Medicine (Professor of Medicine 1994)	
Relevant Clinical Research Experience (please summarize):		
Pfizer Inc, Central Research: 1998-present		
<ol style="list-style-type: none"> 1. Designing, building and leading a global clinical immunology consulting group and Safety Council to provide expert advice to all Therapeutic areas that are developing Biotherapeutics 2. Senior technical expert on Inflam; Chair Inflam Technical Review Committee, Inflam Clinical Line Head 3. Single point of accountability for overall clinical program goals for the — Immunology Portfolio (JAK3 inhibitor for Transplantation and Rheumatoid Arthritis; ————— targeted programs in Discovery) 4. Single point of accountability for overall program goals for the late stage development of the TNF alpha blocking biologic, CDP-870, collaboration with Celltech plc. 5. Providing overall clinical R&D direction to the Pfizer Pharmacia COX-2 Alliance development programs for celecoxib and valdecoxib, leading to successful licensing of Celebrex for acute pain and primary dysmenorrhea (October 2001) and valdecoxib (Bextra) for OA/RA and primary dysmenorrhea (November 2001) and submission of valdecoxib's MAA (Jan 2001). 6. Provided strategic clinical support for Pfizer-Searle COX-2 Alliance Portfolio during filing and launch of celecoxib and valdecoxib and ongoing support of second generation COX-2 inhibitor life cycle programs 7. Provided Clinical Development representation on multidisciplinary teams supporting in-house early drug candidate development for pain, rheumatoid arthritis, osteoarthritis and other inflammatory indications. 8. Supported two active Product In-Licensing Opportunity Teams (Inflammation and Immunology) 		